

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5886842

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NEXIS VISION, INC.	12/27/2019
RECEIVING PARTY DATA	
Name:	NEXIS VISION LIQUIDATING TRUST
Street Address:	191 JEFFERSON DRIVE
City:	MENLO PARK
State/Country:	CALIFORNIA
Postal Code:	94025
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15684010
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	858-350-2300
Email:	patentdocket@wsgr.com, lford@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	47441-704.301
NAME OF SUBMITTER:	LORI FORD
SIGNATURE:	/Lori Ford/
DATE SIGNED:	12/27/2019
Total Attachments: 2	
source=47441-704 Confirmatory Corp Assignment Nexis Vision Inc. to Nexis Vision Liquidating Trust FULLY EXECUTED#page1.tif	
source=47441-704 Confirmatory Corp Assignment Nexis Vision Inc. to Nexis Vision Liquidating Trust FULLY EXECUTED#page2.tif	

CONFIRMATORY CORPORATE TO CORPORATE ASSIGNMENT

Docket Number 47441-704

WHEREAS, Nexis Vision, Inc., also referred to as NexisVision, Inc. (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

SEE ATTACHED SCHEDULE A

WHEREAS, Nexis Vision Liquidating Trust, having a place of business at 191 Jefferson Drive, Menlo Park, CA 94025, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby confirm that the Assignor has sold, assigned, transferred and conveyed unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Assignor hereby confirms that the Assignor has covenanted and agreed to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

ASSIGNOR: Nexis Vision, Inc., also referred to as NexisVision, Inc.

Date: 12/27/2019

Signature: _____

Name: K. Angela Macfarlane
Title: Board Member

RECEIVED AND

AGREED TO BY ASSIGNEE: Nexis Vision Liquidating Trust

Date: 12/27/2019

Signature: _____

Name: K. Angela Macfarlane
Title: Trustee

CONFIRMATORY CORPORATE TO CORPORATE ASSIGNMENT

Docket Number 47441-704

SCHEDULE A

Attorney Docket No.	Country	Application No.	Filing Date	Patent No.	Issue Date	Title
47441-704.101	US	61/279,612	23-Oct-2009			CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.601	WO	PCT/US2010/053854	22-Oct-2010			CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.831	US	13/503,841	20-Aug-2012			CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.301	US	15/684,010	23-Aug-2017			CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.611	EP	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.621	DE	602010045120.8	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.631	FR	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.641	GB	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.650	AT	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.653	CH	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.658	ES	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.663	IT	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.666	NL	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.669	SE	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.901	NO	10825787.4	22-Oct-2010	2490635	06-Sep-2017	CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN
47441-704.6111	EP	17183160.5	22-Oct-2010			CORNEAL DENERVATION FOR TREATMENT OF OCULAR PAIN